Back to results
US 2024/0325339 A1Published application
Melatonin agonist treatment
AssigneeVanda Pharmaceuticals Inc.
InventorsGunther P. Birznieks, Deepak Phadke, Mihael H. Polymeropoulos
Life of this patent
Estimating the term…
Abstract
Melatonin Agonist, MA-1, is administered at effective doses.
Claims1
A pharmaceutical composition in oral unit dose form comprising:
- (1) 20 mg of (1 R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl] methyl]propanamide:
- and
- (2) pharmaceutically acceptable excipients comprising colloidal silicon dioxide;
- croscarmellose sodium;
- and magnesium stearate.
2 more elements
Dependencies are inferred from the claim text.